2020
DOI: 10.36849/jdd.2020.4679
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Impetigo in the Pediatric Population: Consensus and Future Directions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
53
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(53 citation statements)
references
References 0 publications
0
53
0
Order By: Relevance
“…8,9 Bacterial resistance is reported to many antibiotics prescribed for the treatment of impetigo, including mupirocin, retapamulin, and fusidic acid. [10][11][12][13][14][15] Another more recent therapeutic option is Ozenoxacin cream 1%, which has been developed for the first-line treatment of impetigo in patients from two months and up in the U.S. and Canada and six months in E.U. countries.…”
Section: The Algorithmmentioning
confidence: 99%
See 4 more Smart Citations
“…8,9 Bacterial resistance is reported to many antibiotics prescribed for the treatment of impetigo, including mupirocin, retapamulin, and fusidic acid. [10][11][12][13][14][15] Another more recent therapeutic option is Ozenoxacin cream 1%, which has been developed for the first-line treatment of impetigo in patients from two months and up in the U.S. and Canada and six months in E.U. countries.…”
Section: The Algorithmmentioning
confidence: 99%
“…This bactericidal topical non-fluorinated quinolone has been studied in seventeen clinical trials to date but has not yet been incorporated in published practice guidelines for impetigo treatment. 10 Ozenoxacin has been shown to be highly effective against S. pyogenes and S. aureus, including methicillin-susceptible and resistant strains (MRSA). 42,43 Additionally, preliminary data show ozenoxacin's capacity to eradicate biofilm-forming MRSA at therapeutic concentrations.…”
Section: The Algorithmmentioning
confidence: 99%
See 3 more Smart Citations